A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy
Clinical trial NCT03675308 · ACTIVE_NOT_RECRUITING
Trial details
- NCT number
- NCT03675308
- Sponsor
- AbbVie
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- Phase 3
- Study type
- INTERVENTIONAL
- Start date
- 2019-03-25
- Primary completion
- 2020-10-08
- Enrollment
- 964
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.